Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations

  Fibrocell Science Appoints Robert Sheroff, Vice President of Technical
  Operations

    Sheroff in new position will manage expanding footprint of fibroblast
                          manufacturing technologies

Business Wire

EXTON, Pa. -- January 6, 2014

Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company
primarily focused on developing first-in-class treatments for skin diseases
and conditions with high unmet medical needs, today announced that Robert
Sheroff has been appointed vice president of technical operations for the
company. In this newly-created position, Mr. Sheroff will be responsible for
managing the growing manufacturing needs of azficel-T, as well as
manufacturing genetically-modified fibroblast based products.

“We are advancing azficel-T for additional indications, including restrictive
burn scarring and vocal cord scarring, and look forward to filing IND’s for
our genetically-modified fibroblast products targeting orphan diseases through
our collaboration with Intrexon Corporation (NYSE:XON),” said David Pernock,
chairman and chief executive officer of Fibrocell Science. “Manufacturing is
key to our future endeavors and we are pleased that Bob will lead these
efforts.”

Mr. Sheroff is experienced in managing complex pharmaceutical and biologic
manufacturing systems at several biotechnology and pharmaceutical companies.
Before joining Fibrocell, he was senior vice president of global operations at
Biogen-Idec and was responsible for supply-chain logistics and external
manufacturing. Prior to his tenure at Biogen-Idec, Mr. Sheroff was vice
president of the Janssen Supply Group, a division of Johnson & Johnson. He was
responsible for creating and managing the division’s pharmaceutical supply
chain as well as improving coordination between commercial and R&D teams. He
successfully introduced numerous new products across a range of therapeutic
categories and led the integration of the Crucell acquisition into the Janssen
supply chain. While at Johnson & Johnson, he was also vice president of
worldwide operations at Centocor and managed and oversaw the scale-up and
manufacture of Remicade®. Mr. Sheroff has a B.Sc. in Pharmacy from the Rutgers
College of Pharmacy and an M.B.A. in Pharmaceutical Marketing from Fairleigh
Dickinson University.

“Fibrocell’s autologous fibroblast technology has the potential to create
therapies that could have a significant impact on a number of disorders for
which there are poor therapeutic options today,” said Mr. Sheroff. “I am
looking forward to working with the team to develop and execute on these
strategic initiatives.”

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company
primarily focused on developing first-in-class treatments for skin diseases
and conditions with high unmet medical needs. Based on its proprietary
autologous fibroblast technology, Fibrocell is pursuing breakthrough medical
applications of azficel-T for restrictive burn scarring and vocal cord
scarring. The company’s collaboration with Intrexon Corporation (NYSE:XON), a
leader in synthetic biology, includes using genetically-modified fibroblasts
for treating orphan skin diseases for which there are no currently approved
products and exploring the localized treatment of the most common autoimmune
skin disease, moderate-to-severe psoriasis.

Fibrocell’s collaboration with UCLA—focusing on skin-derived stem cells and
more efficient ways to convert skin cells to other cell types—holds potential
for future discovery and development of autologous cellular therapeutics. For
additional information, visit www.fibrocellscience.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. While management has based any forward-looking
statements contained herein on its current expectations, the information on
which such expectations were based may change. Forward-looking statements
include, without limitation, the filing of IND’s for our genetically-modified
fibroblast products targeting orphan diseases. These forward-looking
statements rely on a number of assumptions concerning future events and are
subject to a number of risks, uncertainties, and other factors, many of which
are outside of the Company’s control, that could cause actual results to
materially differ from such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those set forth under
Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2012, as updated in “Item 1A. Risk Factors” in the
Company’s Quarterly Reports on Form 10-Q filed since the annual report. The
Company operates in a highly competitive and rapidly changing environment,
thus new or unforeseen risks may arise. Accordingly, investors should not
place any reliance on forward-looking statements as a prediction of actual
results. The Company disclaims any intention to, and undertakes no obligation
to, update or revise any forward-looking statements. Readers are also urged to
carefully review and consider the other various disclosures in the Company’s
public filings with the SEC.

Contact:

Corporate:
Fibrocell Science
Greg Weaver, 484-713-6022
Chief Financial Officer
gweaver@fibrocellscience.com
or
Investor Relations:
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650
susan@sanoonan.com